Sanifit is a biopharmaceutical company focused on calcification disorders. The company was founded in 2007 as a spin-off of the University of the Balearic Islands and expanded its activities in the USA in 2016 with the incorporation of a subsidiary with offices in San Diego. The company's lead asset, SNF472, has successfully completed a Phase 2 proof of concept study in calciphylaxis, with a Phase 3 pivotal study planned to initiate in 2H 2018. The company is also investigating SNF472 in a Phase 2b study in CV-ESRD, with results expected in Q4 2019. Sanifit has raised more than $50M, including a series C funding of $41.3M (€36.6M) in mid-2015.